GGrantIndex
← Leaderboards

Jane Hoyt Buckner

Benaroya Research Inst At Virginia Mason

$93,413,622
Attributed
$156,838,913
Total exposure
18
Grants
17
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $44.5M · FY200525
$50M$37.5M$25M$12.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$156,838,913 · 18

By mechanism

UM1$109,607,005 · 1
R01$20,501,304 · 6
U01$15,085,529 · 2
DP3$5,154,508 · 2
U19$3,123,762 · 1
R21$2,157,505 · 3

Top collaborators

Most similar at Benaroya Research Inst At Virginia Mason

Same institution · by research overlap

Others in their field

Top investigators on “Autoimmune Diseases

Research focus

Autoimmune DiseasesAutoimmunityT-LymphocyteImmuneInsulin-Dependent Diabetes MellitusCellsLeadSignal TransductionImmune ResponseSamplingLinkResearch PersonnelGeneticGrantPlayImmunologicsResponseRegulatory T-LymphocyteProgramsInsightCytokinePhenotypeCd4 Positive T LymphocytesCohort

Grant awards (63)

Immune Tolerance Network$27,297,773
UM1 · FY2025 · AI · contact PI
Immune Tolerance Network$5,707,872
UM1 · FY2025 · AI · contact PI
Harnessing engineered T regulatory cells to promote beta cell health in T1D$975,699
R01 · FY2025 · DK · contact PI
Regulatory T cells maintain immune homeostasis through translation control$831,400
R01 · FY2025 · AI
Clinical Core$773,306
U19 · FY2025 · AI · contact PI
Build to LEAD - Building partnerships to Link the Exposome to Autoimmune Disease (Administrative Supplement)$526,999
R21 · FY2025 · AR · contact PI
T Cell Epigenomic Drivers of Disease Flares in Multiple Sclerosis$216,625
R21 · FY2025 · AI · contact PI
Immune Tolerance Network$26,502,056
UM1 · FY2024 · AI · contact PI
Immune Tolerance Network UM1 2023 Supplement$7,500,000
UM1 · FY2024 · AI · contact PI
Immune Tolerance Network-NIDDK 2024 Supplement$2,642,000
UM1 · FY2024 · AI · contact PI
T cells promoting transitions toward autoimmunity$1,297,273
U01 · FY2024 · AI · contact PI
Immune Tolerance Network: SUNBEAM Multi-year Supplement$1,000,013
UM1 · FY2024 · AI · contact PI
Clinical Core$988,066
U19 · FY2024 · AI · contact PI
Harnessing engineered T regulatory cells to promote beta cell health in T1D$975,699
R01 · FY2024 · DK · contact PI
Regulatory T cells maintain immune homeostasis through translation control$888,447
R01 · FY2024 · AI
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy$465,623
R01 · FY2024 · CA · contact PI
Proteomic analysis of hydroxychloroquine prevention trials in T1D, RA and SLE$365,178
U01 · FY2024 · AI · contact PI
T Cell Epigenomic Drivers of Disease Flares in Multiple Sclerosis$259,950
R21 · FY2024 · AI · contact PI
Immune Tolerance Network$32,108,233
UM1 · FY2023 · AI · contact PI
Immune Tolerance Network$6,849,058
UM1 · FY2023 · AI · contact PI
T cells promoting transitions toward autoimmunity$1,316,264
U01 · FY2023 · AI · contact PI
Clinical Core$1,036,124
U19 · FY2023 · AI · contact PI
Harnessing engineered T regulatory cells to promote beta cell health in T1D$975,699
R01 · FY2023 · DK · contact PI
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy$845,601
R01 · FY2023 · CA · contact PI
Anti-tumor and autoimmunity signatures in Down syndrome$648,776
R01 · FY2023 · CA · contact PI
Build to LEAD – Building partnerships to Link the Exposome to Autoimmune Disease$492,707
R21 · FY2023 · AR · contact PI
Build to LEAD – Building partnerships to Link the Exposome to Autoimmune Disease (Admin Supp)$260,230
R21 · FY2023 · AR · contact PI
Harnessing engineered T regulatory cells to promote beta cell health in T1D$993,436
R01 · FY2022 · DK · contact PI
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy$901,309
R01 · FY2022 · CA · contact PI
Clinical Core$326,266
U19 · FY2022 · AI · contact PI
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy$423,377
R01 · FY2021 · CA · contact PI
Mechanisms of IL-6 mediated T cell pathogenesis in autoimmunity$2,100,193
R01 · FY2020 · AI · contact PI
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy$946,097
R01 · FY2020 · CA · contact PI
Mechanisms of IL-6 mediated T cell pathogenesis in autoimmunity$841,259
R01 · FY2020 · AI · contact PI
COVID Immunophenotyping Study$543,574
R01 · FY2020 · AI · contact PI
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy$874,780
R01 · FY2019 · CA · contact PI
Mechanisms of IL-6 mediated T cell pathogenesis in autoimmunity$849,019
R01 · FY2019 · AI · contact PI
Exploring novel disease mechanisms in RA linked to HLA class II risk$182,270
R21 · FY2019 · AR · contact PI
Mechanisms of IL-6 mediated T cell pathogenesis in autoimmunity$1,214,057
R01 · FY2018 · AI · contact PI
Exploring novel disease mechanisms in RA linked to HLA class II risk$218,724
R21 · FY2018 · AR · contact PI
Mechanisms of IL-6 mediated T cell pathogenesis in autoimmunity$841,539
R01 · FY2017 · AI · contact PI
Defining the role of altered cytokine signaling pathways on autoimmunity$2,450,784
U01 · FY2016 · AI · contact PI
Defining the role of altered cytokine signaling pathways on autoimmunity$2,450,784
U01 · FY2015 · AI · contact PI
Defining the role of altered cytokine signaling pathways on autoimmunity$2,450,784
U01 · FY2014 · AI · contact PI
Investigating the role of IL-6 signaling in Teff resistance and T1D development$752,476
DP3 · FY2014 · DK · contact PI
Impact of the autoimmunity associated PTPN22 1858T$445,835
R01 · FY2014 · AI · contact PI
Defining the role of altered cytokine signaling pathways on autoimmunity$2,303,678
U01 · FY2013 · AI · contact PI
Impact of the autoimmunity associated PTPN22 1858T$419,085
R01 · FY2013 · AI · contact PI
Defining the functional impact of T1D genes in mouse and man: a unified strategy$143,395
DP3 · FY2013 · DK · contact PI
Defining the functional impact of T1D genes in mouse and man: a unified strategy$4,258,637
DP3 · FY2012 · DK · contact PI
Defining the role of altered cytokine signaling pathways on autoimmunity$2,450,784
U01 · FY2012 · AI · contact PI
Impact of the autoimmunity associated PTPN22 1858T$445,835
R01 · FY2012 · AI · contact PI
Impact of the autoimmunity associated PTPN22 1858T$429,077
R01 · FY2011 · AI · contact PI
Impact of the autoimmunity associated PTPN22 1858T$455,467
R56 · FY2010 · AI · contact PI
Understanding regulatory defects T1D: natural history and impact of therapy$389,663
RC4 · FY2010 · DK · contact PI
Linking Genetic Variation in the PTPN2 Gene to Autoimmune Disease Susceptibility$181,170
R03 · FY2010 · DA · contact PI
Activation Induced Generation of Human Regulatory T Cells$64,969
R01 · FY2010 · DK · contact PI
Activation Induced Generation of Human Regulatory T Cells$303,240
R01 · FY2009 · DK · contact PI
Linking Genetic Variation in the PTPN2 Gene to Autoimmune Disease Susceptibility$183,000
R03 · FY2009 · DA · contact PI
Activation Induced Generation of Human Regulatory T Cells$303,240
R01 · FY2008 · DK · contact PI
Activation Induced Generation of Human Regulatory T Cells$309,429
R01 · FY2007 · DK · contact PI
Activation Induced Generation of Human Regulatory T Cells$318,670
R01 · FY2006 · DK · contact PI
Activation Induced Generation of Human Regulatory T Cells$326,340
R01 · FY2005 · DK